Introduction
Over the past decade, the understanding of human cancer and development of molecular targeted therapies have benefitted from genomic technologies (1) . A large proportion of patients with cancer suffer adverse effects from molecular targeted or cytotoxic agents while exhibiting no effective response in terms of tumor shrinkage (2) . Although molecular targeted therapy is a standard cancer treatment, anticancer therapies using cytotoxic drugs remain a gold standard approach for cancer treatment (3) (4) (5) . The efficacy of cytotoxic anticancer drugs varies among individual patients (6) (7) (8) . Although a number of recent studies have attempted to establish a diagnostic method for predicting chemosensitivity (9) (10) (11) (12) , to the best of our knowledge, no clinically applicable genetic markers for the prediction of sensitivity or resistance to cytotoxic anticancer drugs have been developed. In order to distinguish which patients may respond to certain drugs from those who may not, prior to initiating treatment, to offer a 'cancer precision medicine' program of more effective chemotherapy and also to relieve patients from severe adverse events, a larger set of genetic variants in tumors must be identified to serve as accurate predictive markers for each anticancer drug.
The development of next generation sequencing technologies has revolutionized cancer genomic research because it provides a comprehensive method of detecting genomic alterations (somatic mutations) in cancer cells (13) (14) (15) . A number of studies have reported an association between clinical outcomes and variant allele frequencies (VAFs) in tumors (16) (17) (18) (19) (20) with cancer, such as oncogenes or tumor suppressor genes expressed in cancer cells (21) (22) (23) , the present study hypothesized that the genetic variants of these genes within the tumors may serve important roles in determining the response to cytotoxic anticancer drugs.
In the current study, to identify genetic markers for sensitivity or resistance to 9 cytotoxic anticancer drugs, all exons of 409 genes associated with cancer from 79 cancer xenografts in mice that had been established from 12 different human organs were sequenced. The association between single nucleotide variants (SNVs) detected in the xenografts and sensitivities to the 9 cytotoxic anticancer drugs were then investigated using a nonparametric approach. The present study identifies the genes associated with cancer that may also be associated with sensitivity to ≥1 of the 9 anticancer drugs examined. The results of the current study may help to elucidate the mechanism that causes the different clinical responses to chemotherapy among patients and may be applicable in the development of a prediction system to optimize treatment.
Materials and methods

Xenografts, anticancer drugs and examination of xenografts for sensitivity to anticancer drugs.
A total of 79 human cancer xenografts, including 12 breast cancers, 12 gastric cancers, 10 neuroblastomas, 10 non-small-cell lung cancers, 7 gliomas, 6 pancreatic cancers, 5 colon cancers, 5 choriocarcinomas, 4 small-cell lung cancers, 4 hematopoietic cancers, 3 ovarian cancers and 1 osteosarcoma were transplanted to athymic BALB/c-nu/nu mice (weight, 26.3±1.8 g; age, 8-10 weeks) and maintained by serial subcutaneous transplantation of 2x2x2 mm fragments into the flank once a month as described previously (24) . A total of 7,900 mice were purchased from Japan CLEA Inc. (Tokyo, Japan) and housed in a controlled temperature of 23±1˚C and relative humidity 50-70%, with ad libitum access to food and water. Mice were divided into 10 groups of 6 mice, per xenograft. A total of 79 human tumor tissues from 79 patients were obtained aseptically during surgery or autopsy at 13 hospitals. Mitomycin C (MMC), adriamycin (ADR; both Kyowa Hakko Bio Co., Ltd., Tokyo, Japan), cyclophosphamide (CPM), vincristine (VCR), vinblastine (VLB; all Shionogi & Co. Ltd., Osaka, Japan), nimustine (ACNU; Daiichi Sankyo Co., Ltd., Tokyo, Japan), cisplatin (DDP), 5-fluorouracil (5FU; both Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) and methotrexate (MTX; Wyeth Lederle Japan, Ltd., Tokyo, Japan) were dissolved in sterile 0.85% NaCl containing 1% mannitol (Wako Pure Chemical Industries, Ltd., Osaka, Japan). The maximum tolerated dose for these drugs in mice was determined as described previously [MMC: 6.7 mg/kg, CPM: 260 mg/kg, ACNU: 48 mg/kg, DDP: 10 mg/kg, ADR: 12 mg/kg, VCR: 1.6 mg/kg, VLB: 11 mg/kg, 5-FU: 19 mg/kg (x5), MTX: 15 mg/kg (x5)] (24) . Each anticancer drug was administered individually, at the maximum tolerated dose, to nude mice bearing human cancer xenografts (in groups of 6). Administration route was intravenous infusion in all cases. 5-FU and MTX were administered for 5 days and all other drugs in a single dose. The control group did not receive any treatment (6 mice per xenograft). Chemosensitivity was calculated as the relative tumor volume of treated mice (T) with respect to control (C) using the mean values for the treatment and control groups on day 14, as described previously [T/C (%)] (25, 26) . All animal studies were approved by the institutional committee of Central Institute for Experimental Animals, and conducted according to previously described protocols (27) . Mice were sacrificed 21 days after drug administration.
Gene expression analysis. Total RNA was extracted from xenograft untreated tissues using ISOGEN (Nippon Gene Co., Ltd., Toyama, Japan) according to the manufacturer's protocol. To eliminate genomic DNA contamination, samples were treated with Recombinant DNase (RNase-free; Takara Bio, Inc., Otsu, Japan) following the manufacturer's protocol. cDNA was prepared from 5 µg total RNA using SuperScript III reverse transcriptase (Thermo Fisher Scientific, Inc., Waltham, MA, USA). Firstly, 5 µg total RNA, 1 µl oligo dT primers (Invitrogen; Thermo Fisher Scientific, Inc.) and diethyl pyrocarbonate (DEPC) water were mixed to a total volume of 16 µl. This mixture was incubated at 70˚C for 10 min and then chilled on ice for 5 min. The following components were added: 5 µl 5X first strand buffer (Invitrogen; Thermo Fisher Scientific, Inc.), 1 µl 25 mM dNTP (Wako Pure Chemical Industries, Ltd.), 2.5 µl 100 mM DTT (Invitrogen; Thermo Fisher Scientific, Inc.) and 0.5 µl Recombinant RNase Inhibitor (Takara Bio, Inc.), followed by 1.5 µl SuperScript III Reverse Transcriptase. This reaction mixture was incubated at 42˚C for 50 min and terminated by heating to 70˚C for 15 min. The cDNA products were stored at -20˚C until required. mRNA expression profiles were obtained from an in-house cDNA microarray consisting of 23,040 genes, as described previously (25, 26) . For the 69 genes (Table I) whose expression was not available in the aforementioned profile, reverse transcription-quantitative polymerase chain reaction (RT-qPCR) was completed, using the SYBR Green Real-Time PCR system (Thermo Fisher Scientific, Inc.) and the StepOnePlus and 7900HT Fast Real-time PCR system (Applied Biosystems; Thermo Fisher Scientific, Inc.), following the manufacturer's protocols. Each PCR reaction mixture contained 5 µl Fast SYBR Green Master Mix (2x) (Applied Biosystems; Thermo Fisher Scientific, Inc.), 0.2 µl of each primer (10 pmol/µl) (Sigma-Aldrich; Merck KGaA), 1 µl cDNA and DEPC water (Ambion; Thermo Fisher Scientific, Inc.), for a total volume of 10 µl. The reaction was performed at 95˚C for 20 sec, 40 cycles of 95˚C for 3 sec and 60˚C for 30 sec, 95˚C for 15 sec, 60˚C for 1 min and 95˚C for 15 sec. The sequences of the primers are shown in Table I . The level of mRNA was assessed using the relative standard curve method, relative to β-actin reference gene (28) .
Sample preparation and targeted next-generation sequencing.
Tumor genomic DNA was extracted from 79 xenografts using the QIAmp DNA Mini kit (QIAGEN, Hilden, Germany) according to the manufacturer's protocol. In the screening study, targeted next generation sequencing was performed in 59 xenografts (12 breast cancers, 12 gastric cancers, 10 neuroblastomas, 10 non-small-cell lung cancers, 7 gliomas, 6 pancreatic cancers, 1 ovarian cancer and 1 osteosarcoma) using the Ion AmpliSeq Comprehensive Cancer Panel (CCP ; Table I . Sequences of primers used for qRT-PCR.
Gene
Primer sequence
Forward 5'-ACTTAGGTGACTACCAACTGGG-3' 
Thermo Fisher Scientific, Inc.), which targets the exons of 409 tumor suppressor genes and frequently cited and mutated oncogenes. DNA concentrations were determined using the TaqMan RNase P Detection Reagents kit (Thermo Fisher Scientific, Inc. Statistical analysis. Xenografts were classified into three groups according to variant allele frequencies (VAFs), low (<10%), middle (10-90%) and high (>90%), and the difference of sensitivity to each anticancer drug (T/C (%)) among the groups was examined using a nonparametric approach (Mann-Whitney U-test for two groups or Kruskal-Wallis test for three groups). To identify genes, which may distinguish patients who may respond to the anticancer drugs, from those who may not, SNVs of which the difference between the maximum and the minimum VAF was <50% were removed from further analysis. P<8.39x10 -5 (0.05/596) was determined to indicate a statistically significant difference in the replication study for the adjustment of multiple testing by the strict Bonferroni correction. A Pearson correlation coefficient was performed to estimate the association between the gene expression and sensitivity to each anticancer drug. Combination effects were investigated by totaling the score of each VAF group.
Results
Identification of the candidate SNVs associated with chemosensitivity.
To identify genetic variants significantly associated with the efficacy of one or more of nine anticancer drugs (5FU, ACNU, ADR, CPM, DDP, MMC, MTX, VCR and VLB) examined in the current nude mice system, all exons of 409 genes associated with cancer using 59 xenografts derived from breast cancer, gastric cancer, neuroblastoma, non-small-cell lung cancer, glioma, pancreatic cancer, ovarian cancer and osteosarcoma at the screening stage were sequenced. A total of 5,494 SNVs were identified in the sequence analysis of the 59 xenografts, and the median number of SNVs called in one sample was 988. A total of 2,206 SNVs with a difference between the maximum and the minimum VAF <50% were removed from further analysis, and 2,087, 2,134, 2,134, 2,134, 2,134, 2,134, 1,944, 2,124 and 2,124 SNVs were assessed for sensitivity to 5FU, ACNU, ADR, CPM, DDP, MMC, MTX, VCR and VLB, respectively. The xenografts were classified into three groups, low (<10%), middle (10-90%) and high (>90%) VAF, and the association between the VAF group and sensitivities to cytotoxic anticancer drugs was assessed using the Kruskal-Wallis test or Mann-Whitney U-test. Chemosensitivity was calculated as T/C and the variants whose allele frequency was higher in xenografts with lower T/C as were defined as 'chemosensitive variants' and variants whose allele frequency were higher in xenografts with higher T/C as 'chemoresistant variants'. As presented in Table II , when 59 xenografts were analyzed in a screening study, 43-98 SNVs exhibited a potential association with sensitivity to the aforementioned 9 drugs. The top 10 variants that revealed the smallest P-values are displayed in Tables III-XI . In the screening study using 59 xenografts, three SNVs were observed to exhibit associations (P<0.001) with the associated genes; rs1805321 (P=0.00018; Table I . Continued.
Gene
and X). The xenografts with higher VAFs of rs1805321 and rs62456182 demonstrated an increased response to VCR compared with those that exhibited a lower variant allele frequency of the two SNVs (Table X) . By contrast, xenografts with higher VAFs of rs13382825 exhibited a decreased response to MMC compared with those that presented with lower variant allele frequencies (Table VIII) , suggesting that this genetic variant is associated with resistance to MMC.
Replication study using additional xenografts. To further validate the result of the screening-stage analysis, a replication study was performed, using 596 SNVs showing P<0.05 in ≥1 anticancer drugs in the screening set using independent samples of 20 xenografts. No SNVs revealed significant levels of association in the replication study following Bonferroni correction, including rs1805321, rs62456182 and rs13382825, which demonstrated an association (P<0.001) with VCR (no. 1 and 2; Table X ) and MMC (no. 1; Table VIII) in the screening study. A combined result of the screening and replication studies suggested potential associations of 35 SNVs, which exhibited a stronger association in the combined study than those in screening study, with sensitivity to ≥1 anticancer drugs (Table XII) . However, significant association was not observed in these SNVs (0.0011<P combined <0.035 in Table XII) following Bonferroni correction. The SNV which revealed the lowest P-value in the combined study was rs79555258 (no. 1 in Table XII) in Activin A Receptor Type 2A (ACVR2A; P=0.0011). As presented in Fig. 1 , xenografts with more variant alleles of rs79555258 in the three studies (screening, replication and combined) exhibited a lower response to CPM than those with less variant alleles, suggesting that this variant may be associated with resistance to CPM.
Identification of SNVs associated with multi-drug sensitivity.
Of the 35 SNVs, that demonstrated a potential association with sensitivity to ≥1 anticancer drugs examined, rs16903989 and rs201432181 (no. 16 and 3, respectively; Table XII) were commonly associated with sensitivity to 2 (VCR and CPM) and 4 (ACNU, MMC, VLB and ADR) drugs, respectively. Xenografts with more variant alleles in rs16903989, which is located in intron 9 of Leukemia Inhibitory Factor Receptor Alpha (LIFR), exhibited a higher response to VCR and CPM (P combined =0.0098 and 0.026, respectively; Table XII ). The correlation analysis between gene expression and drug sensitivity demonstrated a significantly positive correlation between the expression level of LIFR and sensitivity to VCR (r=0.42, P=0.00031) and CPM (r=0.36, P=0.0020) as presented in Table XII (no. 16 ). The xenografts with more variant alleles in rs201432181, which is located in exon 19 of GPR124, demonstrated a higher response to ACNU, MMC, VLB and ADR (P combined =0.0013, 0.0040, 0.017 and 0.029, respectively; no. 3 Table XII) , however, no significant association was observed between the expression level of GPR124 and sensitivity to these 4 cytotoxic anticancer drugs in the present study (ACNU, MMC, VLB and ADR; Table XII ).
Combination analysis with markedly associated SNVs with chemosensitivity.
A combined effect of markedly associated SNVs with chemosensitivity was investigated (P combined <0.01) on sensitivities to ADR, 5FU, ACNU and CPM (Table XII) . The xenografts were scored 0, 1 and 2 based on the allele frequency of the chemosensitive variants (P combined <0.01) as low (<10%), middle (10-90%), and high (>90%), respectively. Furthermore, the xenografts were scored 2, 1 and 0 depending on the allele frequency of the chemoresistant variants (P combined <0.01) as low (<10%), middle (10-90%), and high (>90%), respectively. The xenografts were then classified into 4-6 groups according to the sum of the scores. The combination analysis using rs4589708, rs113962761 and rs1050171 revealed a cumulative effect on sensitivity to ADR (P=0.000012; Fig. 2) . Similarly, combination analysis using strongly associated SNVs with sensitivity to 5FU, ACNU and CPM (P<0.01), also revealed a cumulative effect on sensitivity to them (P=0.00025, P=0.000076 and P=0.00021, respectively, data not shown).
Discussion
The present study conducted two-step association studies between frequencies of SNVs in 409 genes (three VAF groups; <10%, 10-90%, >90%) and the sensitivities to 9 cytotoxic anticancer drugs using 79 human cancer xenografts, and identified 35 SNVs with potential associations to sensitivity or resistance to ≥1 cytotoxic anticancer drugs in a combined study. The SNV demonstrating the lowest P-value in the combined study, rs79555258, is located in intron 9 of the ACVR2A gene, and tumors with more variant alleles of rs79555258 were demonstrated to be more likely to be resistant to CPM. ACVR2A is a receptor for activin A, which is a member of the transforming growth factor-β superfamily of cytokines and a putative tumor suppressor gene that is frequently mutated in microsatellite-unstable colon cancer (29, 30) . Activin participates in the regulation of cell proliferation, differentiation and migration, DNA damage repair and apoptosis (29, (31) (32) (33) . Although the functional relevance of ACVR2A to the sensitivity to CPM remains to be elucidated, the single nucleotide variant (rs79555258) of this gene may be a predictive marker for sensitivity to CPM. Table III . Single nucleotide variants potentially associated with sensitivity to 5-fluorouracil.
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No. rs16903989, which was located in intron 9 of the LIFR gene was commonly associated with sensitivity to CPM and VCR. LIFR forms a heterodimer with a signal transducer, gp130 and leads to activation of the Janus kinase/signal transducer and activator of transcription and mitogen activated protein kinase cascades (34) . LIFR has been demonstrated to be downregulated in breast cancer and was identified as a metastasis suppressor (35, 36) . A single nucleotide polymorphism in LIFR (rs3729740) was reported to be a potential predictive marker for sensitivity to a molecular-targeted drug, cetuximab (37). Furthermore, the expression level of LIFR was revealed to be associated with sensitivity to VCR in glioblastoma cells (38) , and the data of the current study also indicated a positive correlation between the expression level of LIFR and sensitivity to VCR. Although the role of LIFR in response to anticancer therapy has not yet been clarified, this gene may be associated with a common mechanism of drug response. The current study also demonstrated that rs201432181 in GPR124 was typically associated with sensitivity to 4 anticancer drugs (ACNU, ADR, MMC and VLB). rs201432181 is a nonsynonymous substitution (p.D1313 V), and the effect of the substitution on protein function was predicted to be 'possibly damaging' by Polyphen2. GPR124 is known to regulate vascular endothelial growth factor-induced tumor angiogenesis in vitro (39) . Therefore, the promotion of tumor angiogenesis by activation of pathway involved with GPR124 may enhance the delivery of anticancer drugs.
To investigate the tissue specificity of the chemosensitivity-related SNVs identified in the current study, subgroup analysis for breast and gastric cancer xenografts was performed as they included the largest number of tissues (n=12 each) used in the present study. SNVs that were commonly associated with chemosensitivity in the xenografts derived from breast and gastric cancer were identified (rs79555258 for CPM, P=0.031 and 0.086, respectively). By contrast, the study also observed the SNVs associated with chemosensitivity in the xenografts derived from breast cancer, but not in those from gastric cancer.
Of the 409 genes sequenced using CCP in the current study, Excision Repair Cross-Complementation Group 1, Excision Repair Cross-Complementation Group 2, AKT1 and Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit α have previously been reported to be candidates or promising predictors for sensitivity to cisplatin (40) (41) (42) . However, no SNVs associated with these genes demonstrated a significant association with cisplatin in the current study, this is potentially because the sample size was too small. Further studies using a large number of xenografts and clinical samples are required to confirm whether they may be a predictive marker for sensitivity to cisplatin clinically.
In conclusion, the present study used 79 human cancer xenografts implanted into nude mice to identify 35 possible genetic variants associated with the sensitivity or resistance to ≥1 anticancer drugs from a total of 9. These findings provide novel insights into personalized selection of chemotherapy for patients with cancer, however; further functional analysis is required to verify the results of the current study and to clarify their biological mechanisms, which have effects on Figure 1 . Association between rs79555258 and sensitivity to CPM. The xenografts with higher variant allele frequency in rs79555258 exhibited a lower response to CPM compared with those that presented with a lower variant allele frequency. The (A) screening study, (B) replication study and (C) combined study are presented where the sensitivity to CPM is represented by relative tumor volume of T with respect to C. 'x' represents a single xenograft. Boxes represent the interquartile range (IQR) between first and third quartiles and the line inside represents the median. The whiskers outside the box extend to the highest and lowest value within 1.5 times the IQR. CPM, cyclophosphamide; T, treated mice; C, control. Figure 2 . Combined effects of rs4589708, rs113962761 and rs1050171 on sensitivity to ADR. The distribution of ADR sensitivity is presented in the four score groups. The xenografts were classified into four groups based on the sum of the score given to each variant allele frequencies group for the three single nucleotide variants. 'x' represents a single xenograft. Boxes represent the interquartile range (IQR) between first and third quartiles and the line inside represents the median. The whiskers outside the box extend to the highest and lowest value within 1.5 times the IQR. ADR, Adriamycin; T, treated mice; C, control.
the clinical outcomes of patients receiving the chemotherapy. Accumulation of data is expected to lead to 'cancer precision medicine' using more effective and less harmful anticancer drugs.
